Canterbury Health Laboratories wishes to advise that the Serum Infliximab service has recommenced.

“Our Immunology laboratory has verified a commercial ELISA assay, which is utilised internationally, whilst work continues to investigate alternate options. It is important to note that results should not be compared between the previous and current assay, as they utilise different technology. If there are any future changes in assay, this will be communicated at that time.”

As previously communicated, samples received prior to January 2025 will not be reported unless the requester specifically requests us to do so.

Please do not hesitate to contact us if you have any queries and thank you for your patience and support as CHL worked through this issue.